Orthofix MedicalOFIX
OFIX
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
30% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 40
25% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]
6% more capital invested
Capital invested by funds: $543M [Q3] → $577M (+$34M) [Q4]
4% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 24
0% more funds holding
Funds holding: 149 [Q3] → 149 (+0) [Q4]
0% more call options, than puts
Call options by funds: $7K | Put options by funds: $7K
4.55% less ownership
Funds ownership: 91.04% [Q3] → 86.49% (-4.55%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
37%
upside
Avg. target
$23
44%
upside
High target
$24
50%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity Caitlin Burrows 46% 1-year accuracy 12 / 26 met price target | 50%upside $24 | Buy Maintained | 26 Feb 2025 |
Roth MKM Jason Wittes 43% 1-year accuracy 9 / 21 met price target | 37%upside $22 | Buy Reiterated | 26 Feb 2025 |
Financial journalist opinion
Based on 4 articles about OFIX published over the past 30 days
Neutral
Business Wire
1 week ago
Orthofix Receives 510(k) Clearance and CE Mark for TrueLok Elevate Transverse Bone Transport System
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and the European CE Mark for the TrueLok™ Elevate Transverse Bone Transport (TBT) System. TrueLok Elevate provides a limb preservation treatment option for addressing bony or soft tissue deformities and defects such as diabetic foot ulcers and nonhealing or deep tissue wounds. While the TBT.

Neutral
GlobeNewsWire
2 weeks ago
Kuehn Law Encourages Investors of Orthofix Medical Inc. to Contact Law Firm
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Orthofix Medical Inc. (NASDAQ: OFIX) breached their fiduciary duties to shareholders.

Neutral
Business Wire
2 weeks ago
Orthofix Announces Appointment of Vickie Capps to Board of Directors
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. “Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix,” said Michael Finegan, Chairman of Orthofix. “Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously.

Neutral
Business Wire
4 weeks ago
Orthofix to Participate in the 37th Annual Roth Conference
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate in the 37th Annual Roth Conference in Dana Point, CA. Management is scheduled to present on Monday, March 17, 2025 at 8:00 am PT. Interested parties can access the live and archived webcast of the presentation in the “Events & Presentations” section of the Orthofix investor relations website at ir.orthofix.com. Internet Posti.

Neutral
Seeking Alpha
1 month ago
Orthofix Medical Inc. (OFIX) Q4 2024 Earnings Call Transcript
Orthofix Medical Inc. (OFIX) Q4 2024 Earnings Call Transcript

Negative
Zacks Investment Research
1 month ago
Orthofix (OFIX) Q4 Earnings Lag Estimates
Orthofix (OFIX) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.10 per share a year ago.

Neutral
Business Wire
1 month ago
Orthofix Reports Fourth Quarter and Full-Year 2024 Results and Provides 2025 Financial Guidance
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended December 31, 2024, and provided full-year 2025 financial guidance. Highlights Record fourth quarter 2024 net sales of $215.7 million, an increase of 8% on a reported and constant currency basis compared to fourth quarter 2023 U.S. Spine Fixation1 net sales growth of 12% compared to fourth quarter 202.

Neutral
Business Wire
1 month ago
Orthofix to Participate in the Canaccord Genuity 2025 Musculoskeletal Conference
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate in the Canaccord Genuity 2025 Musculoskeletal Conference in San Diego. Management is scheduled to present on Monday, March 10, 2025 at 9:00 am PT. Interested parties can access the live and archived webcast of the presentation in the “Events & Presentations” section of the Orthofix investor relations website at ir.orthofix.co.

Negative
Benzinga
1 month ago
Top 2 Health Care Stocks That May Crash In February
As of Feb. 5, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Neutral
Business Wire
2 months ago
Orthofix to Report Fourth Quarter and Full-Year 2024 Financial Results
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2024 financial results on Tuesday, February 25, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations.

Charts implemented using Lightweight Charts™